Cite
HARVARD Citation
Reck, M. et al. (2019). Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. European journal of cancer. pp. 137-147. [Online].